OpGen (NASDAQ:OPGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
A number of other equities research analysts also recently commented on OPGN. ValuEngine downgraded shares of OpGen from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 25th. HC Wainwright raised their price objective on shares of OpGen to $9.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th.
Shares of OpGen (OPGN) opened at $2.27 on Tuesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.23 and a quick ratio of 1.13. The company has a market cap of $12.00, a PE ratio of -0.15 and a beta of 1.21. OpGen has a 12-month low of $1.78 and a 12-month high of $31.25.
An institutional investor recently raised its position in OpGen stock. Vanguard Group Inc. grew its stake in shares of OpGen Inc (NASDAQ:OPGN) by 1.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 342,860 shares of the medical research company’s stock after acquiring an additional 5,500 shares during the period. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 at the end of the most recent reporting period.
COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Downgrades OpGen (OPGN) to Hold” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/15/zacks-investment-research-downgrades-opgen-opgn-to-hold.html.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.